INOVIO is a clinical-stage biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer and infectious diseases. We use proprietary technology to design DNA plasmids —small circular DNA molecules that work like software that the body’s cells can download to learn how to produce specific proteins to target and fight disease. Our proprietary investigational CELLECTRA® devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors.
LAURENT HUMEAU, Ph.D.
Chief Scientific Officer
“Our research is advancing the next generation of DNA medicine technology and driving innovation in how we treat and protect people from disease.”
Learn More
JACQUELINE SHEA, Ph.D.
PRESIDENT & CHIEF EXECUTIVE OFFICER
“As we prepare to submit our first BLA, INOVIO stands poised to make DNA medicines a reality for patients and stakeholders. We would not be here today without the strategic vision and innovative drive of our uniquely experienced team.”
Learn More
PETER KIES
CHIEF FINANCIAL OFFICER
“DNA medicine has the potential to be transformational for patients around the world. We are dedicated to delivering on that promise.”
Learn More
MICHAEL SUMNER
Chief Medical Officer
“Across our pipeline we’re working to advance DNA medicine and develop innovative, next-generation therapies with groundbreaking potential.”
Learn More
Steve Egge
Chief Commercial Officer
“As we work to bring the first DNA medicine to market in the US, I believe that we can leverage the potential advantages of our platform to redefine the treatment paradigm for HPV-related diseases, cancer and infectious disease.”
Learn More
SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases
© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.
